Pancreatic Cancer Research

ResearcherLanzhou UniversityActive in the last 2 years

Wenkai Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2213-9850; OpenAlex author ID A5024653090. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 4

  1. Cordycepin inhibits pancreatic cancer progression and enhances gemcitabine sensitivity by targeting the CDK2/E2F2 axis to modulate TNNI2 expression. Co-author DOI 10.1016/j.bcp.2026.118299↗
  2. The relationships between antihypertensive medications and the overall survival of patients with pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1080/17474124.2022.2088506↗
  3. The Application of Exosomal MicroRNAs in the Treatment of Pancreatic Cancer and Its Research Progress. First author DOI 10.1097/mpa.0000000000001713↗
  4. Current understanding of ferroptosis in the progression and treatment of pancreatic cancer. Co-author DOI 10.1186/s12935-021-02166-6↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wence Zhou · 4 shared papers, 2021–2026 · strength 1.02
  2. Ru He · 1 shared paper, 2026 · strength 0.43
  3. Ru He · 1 shared paper, 2022 · strength 0.22
  4. Yu Gan · 1 shared paper, 2021 · strength 0.19
  5. Xin Li · 1 shared paper, 2021 · strength 0.19
  6. Xin Li · 1 shared paper, 2021 · strength 0.17
  7. Zhou Chen · 1 shared paper, 2021 · strength 0.17
  8. Shi Dong · 1 shared paper, 2021 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.